Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 306

1.

Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR.

Clin Cancer Res. 2012 Sep 15;18(18):4986-96. doi: 10.1158/1078-0432.CCR-12-0792. Epub 2012 Jul 23.

PMID:
22825581
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.

Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR.

Cancer Biol Ther. 2012 Aug;13(10):935-45. doi: 10.4161/cbt.20846. Epub 2012 Aug 1.

PMID:
22785204
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.

Clin Cancer Res. 2006 Jul 1;12(13):4103-11.

PMID:
16818711
[PubMed - indexed for MEDLINE]
Free Article
4.

Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.

Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, Wang S, Johnson DE, Grandis JR.

Mol Pharmacol. 2008 Jun;73(6):1632-42. doi: 10.1124/mol.107.044636. Epub 2008 Mar 6.

PMID:
18326051
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.

Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR.

Clin Cancer Res. 2010 May 1;16(9):2571-9. doi: 10.1158/1078-0432.CCR-10-0333. Epub 2010 Apr 13.

PMID:
20388852
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

PMID:
16951222
[PubMed - indexed for MEDLINE]
Free Article
7.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

PMID:
15475436
[PubMed - indexed for MEDLINE]
Free Article
8.

Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM.

Clin Cancer Res. 2009 Mar 1;15(5):1585-92. doi: 10.1158/1078-0432.CCR-08-2068. Epub 2009 Feb 3.

PMID:
19190133
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.

Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A.

Cancer Res. 2013 Jun 1;73(11):3381-92. doi: 10.1158/0008-5472.CAN-12-4047. Epub 2013 Apr 10.

PMID:
23576557
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG.

PLoS One. 2013;8(2):e56112. doi: 10.1371/journal.pone.0056112. Epub 2013 Feb 6.

PMID:
23405260
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.

Young NR, Liu J, Pierce C, Wei TF, Grushko T, Olopade OI, Liu W, Shen C, Seiwert TY, Cohen EE.

Mol Oncol. 2013 Jun;7(3):359-68. doi: 10.1016/j.molonc.2012.11.001. Epub 2012 Nov 14.

PMID:
23200321
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.

Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, Saigal K, Mundinger GS, Xu X, Morris JC, Calvo KR, Van Waes C, Chen Z.

Clin Cancer Res. 2009 Apr 1;15(7):2361-72. doi: 10.1158/1078-0432.CCR-08-1011. Epub 2009 Mar 24.

PMID:
19318490
[PubMed - indexed for MEDLINE]
Free Article
13.

Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.

Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM.

Clin Cancer Res. 2011 Jul 1;17(13):4425-38. doi: 10.1158/1078-0432.CCR-10-3339. Epub 2011 May 27.

PMID:
21622718
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.

Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR.

Mol Cancer Ther. 2012 Jun;11(6):1236-46. doi: 10.1158/1535-7163.MCT-11-0936. Epub 2012 Apr 5.

PMID:
22491800
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.

Klein JD, Christopoulos A, Ahn SM, Gooding WE, Grandis JR, Kim S.

Head Neck. 2012 Sep;34(9):1269-76. doi: 10.1002/hed.21917. Epub 2012 Feb 6.

PMID:
22307735
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.

Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR.

Mol Cancer Ther. 2007 Apr;6(4):1414-24.

PMID:
17431120
[PubMed - indexed for MEDLINE]
Free Article
17.

Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.

Cassell A, Freilino ML, Lee J, Barr S, Wang L, Panahandeh MC, Thomas SM, Grandis JR.

Neoplasia. 2012 Nov;14(11):1005-14.

PMID:
23226094
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

PMID:
15289342
[PubMed - indexed for MEDLINE]
Free Article
19.

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.

Clin Cancer Res. 2004 Jan 15;10(2):784-93.

PMID:
14760102
[PubMed - indexed for MEDLINE]
Free Article
20.

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.

Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS.

J Natl Cancer Inst. 2014 Aug 5;106(9). pii: dju215. doi: 10.1093/jnci/dju215. Print 2014 Sep.

PMID:
25099740
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk